The new patent entitled Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy provides protection until December 2019.
Jazz Pharmaceuticals chairman and chief executive officer Bruce Cozadd said, "Our intellectual property, including the patent issued today, reflects the company’s continued commitment to the further understanding of Xyrem and to supporting its safe and effective use."
Till date FDA cleared only Xyrem as the medication for both cataplexy and excessive daytime sleepiness in narcolepsy patients.